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Motor slowing and forebrain white matter loss have been reported in premanifest
Huntington’s disease (HD) prior to substantial striatal neuron loss. These findings raise
the possibility that early motor defects in HD may be related to loss of excitatory input
to striatum. In a prior study, we showed that in the heterozygous Q140 knock-in mouse
model of HD that loss of thalamostriatal axospinous terminals is evident by 4 months,
and loss of corticostriatal axospinous terminals is evident at 12 months, before striatal
projection neuron pathology. In the present study, we specifically characterized the loss of
thalamostriatal and corticostriatal terminals on direct (dSPN) and indirect (iSPN) pathway
striatal projection neurons, using immunolabeling to identify thalamostriatal (VGLUT2+)
and corticostriatal (VGLUT1+) axospinous terminals, and D1 receptor immunolabeling
to distinguish dSPN (D1+) and iSPN (D1−) synaptic targets. We found that the loss
of corticostriatal terminals at 12 months of age was preferential for D1+ spines, and
especially involved smaller terminals, presumptively of the intratelencephalically projecting
(IT) type. By contrast, indirect pathway D1− spines showed little loss of axospinous
terminals at the same age. Thalamostriatal terminal loss was comparable for D1+ and
D1− spines at both 4 and 12 months. Regression analysis showed that the loss of
VGLUT1+ terminals on D1+ spines was correlated with a slight decline in open field motor
parameters at 12 months. Our overall results raise the possibility that differential thalamic
and cortical input loss to SPNs is an early event in human HD, with cortical loss to dSPNs
in particular contributing to premanifest motor slowing.
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INTRODUCTION
Premanifest HD individuals are slowed in initiation and/or exe-
cution of motor tasks (Siemers et al., 1996; de Boo et al., 1997;
Kirkwood et al., 1999, 2000; Blekher et al., 2004; Rao et al.,
2008, 2011; Biglan et al., 2009; Bechtel et al., 2010; Delval et al.,
2011; Tabrizi et al., 2011; Turner et al., 2011). This defect is
mild in individuals not near clinical onset, but more severe in
those near onset (Kirkwood et al., 2000; Rao et al., 2008; Bechtel
et al., 2010; Rupp et al., 2010). Motor symptoms in premanifest
HD occur in parallel with gradual loss of cerebral and striatal
white matter (Kipps et al., 2005; Reading et al., 2005; Ciarmiello
et al., 2006; Paulsen et al., 2006; Rosas et al., 2006; Hobbs et al.,
2010a; Aylward et al., 2011; Dumas et al., 2012), increasing stri-
atal hypometabolism (Grafton et al., 1992; Ciarmiello et al.,
2006), and reduced striatal activation during behavioral tasks
(Paulsen et al., 2004; Wolf et al., 2012). Nonetheless, the few
neuropathological studies of premanifest striatum have reported
some variable neuronal loss in the head of the dorsal caudate, but
little or no neuron loss has been described for the motor striatum
(Vonsattel et al., 1985; Albin et al., 1991; Vonsattel and DiFiglia,
1998).
In a prior study, we examined thalamostriatal and corticos-
triatal input loss over the first year of life in a precise genetic
mimic of human HD, the heterozygous Q140 knock-in mouse
(Deng et al., 2013). Heterozygous Q140 mice are not yet overtly
symptomatic at 1 year of age (and thus comparable to premani-
fest human HD) and show no striatal neuron loss (Rising et al.,
2011; Deng et al., 2013). We found significant deficiencies in tha-
lamic input to the spines and dendrites of striatal neurons by 4
months of age, and substantial loss of cortical input to the spines
of striatal neurons by 1 year. These findings suggest that loss of
thalamostriatal and corticostriatal terminals may contribute to
motor impairments in premanifest HD.
In symptomatic HD, differential loss of direct pathway striatal
projection neurons (dSPNs) vs. indirect pathway striatal pro-
jection neurons (iSPNs) occurs and accounts for the differing
clinical symptoms at different stages of progression (Reiner et al.,
1988; Richfield et al., 1995; Glass et al., 2000; Deng et al., 2004).
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The differential striatal projection neuron (SPN) loss raises the
possibility that any premanifest loss of corticostriatal and/or tha-
lamostriatal terminals from SPNs in humanHD, as we had shown
in Deng et al. (2013) for heterozygous Q140 mice, may be dif-
ferential as well. In the present study, we characterized the loss
of thalamostriatal and corticostriatal axospinous terminals from
dSPNs and iSPNs in heterozygous Q140 mice. The loss of cor-
ticostriatal terminals at 12 months was preferentially for dSPN
spines, and was correlated with a slight decrease in locomotor
activity, consistent with the role of dSPNs neurons in promot-
ing movement and in cortex in driving their activity (Albin et al.,
1989; Kravitz et al., 2010; Spigolon et al., 2013). Thalamostriatal
terminal loss was comparable for D1+ and D1− spines at both
4 and 12 months of age. The results suggest that an early non-
differential deficiency in thalamic input to SPNs, and a later
specific loss of cortical input to dSPNs may occur and contribute
to premanifest HD motor abnormalities.
MATERIALS AND METHODS
ANIMALS
Results from 10 wild-type male (WT) and 10 heterozygous male
Q140 mice (obtained from JAX, Bar Harbor, Maine) are pre-
sented here, and all animal use was carried out in accordance
with the National Institutes of Health Guide for Care and Use
of Laboratory Animals, Society for Neuroscience Guidelines,
and University of Tennessee Health Science Center Guidelines.
Heterozygous HD mutants were studied because the human dis-
ease most commonly occurs due to a single allelic defect. It is also
important to emphasize that most prior behavioral and histolog-
ical work on Q140 mice has focused on homozygous mutants
(Menalled et al., 2003; Hickey et al., 2008, 2012; Lerner et al.,
2012), but one recent study has shown that the heterozygous
Q140 phenotype is milder than that in homozygous Q140 mice
(Rising et al., 2011). Moreover, Rising et al. (2011) did not find
evidence of early hyperactivity in a rearing test at 2.5 months
in either heterozygous or homozygous Q140 mice, in contrast
to Menalled et al. (2003), who reported rearing and open field
hyperactivity at 1 month in homozygous Q140 mice. Thus, the
occurrence of an early hyperactivity in heterozygous Q140 mice
has neither been shown nor disproven. Because deficiencies in
the thalamostriatal projection were evident at 4 months, but loss
of corticostriatal input was not evident until 12 months in our
prior single-labeling study (Deng et al., 2013), in the present
study VGLUT2/D1 double-labeling was analyzed for both 4 and
12 month-old Q140 and WT mice, while VGLUT1/D1 double-
labeling was only assessed for 12 month-old Q140 and WT mice.
As in prior studies by us and others, we used D1 immunolabel-
ing to distinguish dSPN spines and dendrites (D1–positive) from
iSPN spines and dendrites (D1–negative) (Day et al., 2006; Lei
et al., 2013). It should be noted that the repeat length in the Q140
mice we used had undergone a spontaneous reduction during
breeding at JAX, and the average CAG repeat length in our five 4-
month old Q140mice was 128.6 ± 1.4, and our five 12-month old
Q140 mice was 135.0 ± 0.9. The range of CAG variation for Q140
mice within each age groupwas small and had no significant effect
on the outcomes measured here, as assessed by regression anal-
ysis. Moreover, Hickey et al. (2008) have suggested that repeat
length variation from 120 to 140 CAG does not substantially alter
the Q140 phenotype originally reported by Menalled et al. (2003)
for 140 CAGmice. Five 4-month oldWTmice, and five 12-month
WT mice were also studied. Note that we refer to our mutant
mice as Q140, despite the slightly shorter CAG repeat length,
to relate our findings to other work on the same mutant strain
(in which the first exon of mouse huntingtin was replaced with
a human equivalent with ∼140 CAG repeats) (Menalled et al.,
2003), as others have done as well (Hickey et al., 2008, 2012;
Lerner et al., 2012). For histological analysis, mice were deeply
anesthetized with 0.2ml of 35% chloral hydrate in saline, and
then exsanguinated by transcardial perfusion with 30ml of 6%
dextran in sodium phosphate buffer (PB), followed by 200ml of
3.5% paraformaldehyde—0.6% glutaraldehyde—15% saturated
picric acid in PB (pH 7.4). The brain of each mouse was removed,
postfixed overnight in 3.5% paraformaldehyde—15% saturated
picric acid in PB. The right side of the brain was used for a prior
light microscopic (LM) (Deng et al., 2013) and the present cor-
tical thickness assessment, and the left for the current electron
microscopic (EM) double-label analysis. The left side of the brain
had also been used in our prior EM single-label analysis (Deng
et al., 2013). For EM studies, forebrain was sectioned at 50µm on
a vibratome.
EM DOUBLE-IMMUNOLABELING FOR VGLUT1 OR VGLUT2 WITH
DOPAMINE RECEPTOR D1
Sections were pretreated with 1% sodium borohydride in 0.1M
PB for 30min followed by incubation in 0.5% H2O2solution
in 0.1M PB for 30min. To carry out conventional double-label
immunohistochemistry, sections were incubated overnight at
room temperature in primary antisera containing guinea pig anti-
VGLUT1 or VGLUT2 (diluted 1:2000) and rat anti D1 (1:400),
or rabbit anti-VGLUT2 (diluted 1:2000) and rat anti D1 (1:400)
with 0.1M PB containing 10% normal horse serum, 4% nor-
mal goat serum, 1.5% bovine serum albumin, and 0.02% Triton
X-100. Sections were then rinsed and incubated in a mixture
of biotinylated goat anti-guinea pig IgG diluted 1:100 and goat
anti-rat IgG diluted 1:100 (to detect guinea pig anti-VGLUT1 or
VGLUT2, and rat anti-D1), or a mixture of goat anti-rabbit IgG
1:100 and goat anti-rat IgG 1:100 (to detect rabbit anti-VGLUT2,
and rat anti-D1) in 0.1M PB (pH 7.4) at room temperature for
1 h. This was followed by incubation in a mixture containing
avidin-biotin complex (ABC) and rat peroxidase-antiperoxidase
(PAP) at a 1:500 dilution (to detect guinea pig anti-VGLUT1 or
VGLUT2, and rat anti-D1), or a mixture of rabbit PAP and rat
PAP (to detect rabbit anti-VGLUT2, and rat anti-D1) in 0.1M
PB (pH 7.4) at room temperature for 2 h. The sections were
rinsed between secondary and ABC and/or PAP incubations in
three 5-min washes of PB. Subsequent to the ABC and/or PAP
incubation, the sections were rinsed with three to six 10-min
washes in 0.1M PB, and a peroxidase reaction using diaminoben-
zidine (DAB) carried out. After the PB rinses, the sections were
immersed for 10min in 0.05% DAB (Sigma, St. Louis, MO)
in 0.1M PB (pH 7.2). Hydrogen peroxide was then added to
a final concentration of 0.01%, and the sections were incu-
bated in this solution for an additional 10min, and washed six
times in PB.
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PREPARATION OF TISSUE FOR EM
Following immunolabeling as described above, sections processed
for EM viewing were rinsed in 0.1M sodium cacodylate buffer
(pH 7.2), postfixed for 1 h in 2% osmium tetroxide (OsO4) in
0.1M sodium cacodylate buffer, dehydrated in a graded series
of ethyl alcohols, impregnated with 1% uranyl acetate in 100%
alcohol, and flat-embedded in Spurr’s resin (ElectronMicroscopy
Sciences, Fort Washington, PA). For the flat-embedding, the sec-
tions were mounted on microslides pretreated with liquid releas-
ing factor (Electron Microscopy Sciences, Fort Washington, PA).
Pieces of embedded tissue were cut from the dorsolateral (motor)
striatum and glued to carrier blocks, and ultrathin sections were
cut from these specimens with a Reichert ultramicrotome. The
sections were mounted on mesh grids, stained with 0.4% lead
citrate and 4.0% uranyl acetate using an LKB Ultrastainer, and
finally viewed and images captured with a JEOL 2000EX electron
microscope.
ANTIBODIES
All VGLUT antisera used are highly selective for their target anti-
gens (Fremeau et al., 2001; Montana et al., 2004; Melone et al.,
2005; Wässle et al., 2006). The immunogen for the VGLUT1
antibody (Chemicon AB5905) was aa542–560 of the C-terminus
of rat VGLUT1, while that for the guinea pig VGLUT2 anti-
body (Chemicon AB5907) was aa565–582 of the C-terminus
of rat VGLUT2. The immunogen for the rabbit VGLUT2 anti-
body (V2514, Sigma) was aa520–538 near the C-terminus of
rat VGLUT2. A previous study of ours demonstrated that the
immunolabeling in rat striatum for the two VGLUT2 antibod-
ies used here shows complete colocalization (Lei et al., 2013).
The rat anti-D1 antibody (Sigma D-187) is directed against
the 97 amino acid C-terminal fragment of human D1 (Hersch
et al., 1995; Wang and Pickel, 2002). The antibody is selective
for D1 in human, primate and rodent brain (Levey et al., 1993;
Hersch et al., 1995; Wang and Pickel, 2002; Lei et al., 2004,
2013).
EM ANALYSIS
Blinded analysis and quantification was carried out on digital EM
images of random fields from dorsolateral somatomotor striatum
(Figure 1). Typically, 25–30 EM images that in total encompassed
400–450µm2 of dorsolateral striatum per marker combination
were analyzed per animal. This typically yielded 45–55 thalamic
and 65–75 cortical terminals per animal per marker combina-
tion in WT mice, but fewer in mutant mice, as described in
the Results Section. We focused on dorsolateral striatum because
matrix compartment neurons of this region are important for
motor function, and because it is poor in striosomes (although
not entirely devoid), and the major target of intralaminar tha-
lamus (Berendse and Groenewegen, 1990; Gerfen, 1992; Desban
et al., 1993; Wang et al., 2007). We performed the analysis on
the upper 5 microns of the sections, in which labeling was opti-
mal. We avoided the very surface, where histology was poor. All
VGLUT-immunolabeled asymmetric synaptic terminals in each
image were tabulated as to their postsynaptic target (spine vs. den-
drite, D1+ vs. D1−) and their size measured. We studied eight
types of synaptic terminals: (1) VGLUT1 corticostriatal terminals
FIGURE 1 | Examples of the fields of view captured in the EM images
used for analysis. Image (A) shows VGLUT1+ immunolabeled synaptic
terminals (ter) on D1+ (arrowheads) and D1− (arrows) spines (sp) and
dendrites (den) in striatum in WT mice at 12 months of age. Image
(B) shows VGLUT2+ immunolabeled synaptic terminals (ter) on D1+
(arrowheads) and D1− (arrows) spines (sp) and dendrites (den) in striatum
in WT mice at 12 months of age. Both images are at the same
magnification.
on D1–positive spines of striatal neurons; (2) VGLUT1 corti-
costriatal terminals on D1–negative spines of striatal neurons;
(3) VGLUT2 thalamostriatal terminals on D1–positive spines
of striatal neurons; (4) VGLUT2 thalamostriatal terminals on
D1–negative spines of striatal neurons; (5) VGLUT1 corticos-
triatal terminals on D1–positive dendrites of striatal neurons;
(6) VGLUT1 corticostriatal terminals on D1–negative dendrites
of striatal neurons; (7) VGLUT2 thalamostriatal terminals on
D1–positive dendrites of striatal neurons; (8) VGLUT2 thalam-
ostriatal terminals on D1–negative dendrites of striatal neurons.
Examples of VGLUT1+ axospinous terminals on D1–positive
(D1+) and D1–negative (D1−) spines at 12 months in WT
and Q140 mice are shown in Figure 2. Examples of VGLUT2+
axospinous terminals on D1+ and D1− spines in WT and Q140
mice at 4 and 12 months are shown in Figures 3, 4, respectively.
Labeled spines and terminals were identifiable by the dark floc-
culent DAB reaction product, and were typically about twice the
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FIGURE 2 | Examples of EM images of VGLUT1+ immunolabeled
synaptic terminals on D1− (A) and D1+ (B) spines in striatum in WT
mice at 12 months of age, and of VGLUT1+ immunolabeled synaptic
terminals on D1− (C) and D1+ (D) spines in striatum in Q140 mice at
12 months of age. All images are at the same magnification.
FIGURE 3 | Examples of EM images of VGLUT2+ immunolabeled
synaptic terminals on D1− (A) and D1+ (B) spines in striatum in WT
mice at 4 months of age, and of VGLUT2+ immunolabeled synaptic
terminals on D1− (C) and D1+ (D) spines in striatum in Q140 mice at 4
months of age. All images are at the same magnification.
darkness of unlabeled structures. Only terminals with an overt
synaptic contact possessing a PSD (post-synaptic density) were
counted and measured, since all VGLUT terminals are excitatory
and their synaptic contacts evidenced by the presence of vesicles
in the terminal and a PSD in the target spine or dendrite (Deng
et al., 2013; Lei et al., 2013). The size of terminals was determined
bymeasuring them at their widest diameter parallel to and 0.1µm
FIGURE 4 | Examples of EM images of VGLUT2+ immunolabeled
synaptic terminals on D1− (A) and D1+ (B) spines in striatum in WT
mice at 12 months of age, and of VGLUT2+ immunolabeled synaptic
terminals on D1− (C) and D1+ (D) spines in striatum in Q140 mice at
12 months of age. All images are at the same magnification.
before the postsynaptic density, and spines were identifiable by
their small size, continuity with dendrites, prominent postsynap-
tic density, and/or the presence of spine apparatus (Wilson et al.,
1983). Dendrites were identifiable by their size, oval or elongate
shape, and the presence of microtubules and mitochondria. As
we have previously noted (Reiner et al., 2010), these measure-
ments were made in random sections that did not necessarily pass
through the widest point of each terminal, and thus may underes-
timate the peak size of the labeled terminals in three dimensions.
Nonetheless, we have previously noted based on semi-serial sec-
tions that this underestimate is only about 10% (Reiner et al.,
2010), and our goal was to compare WT and Q140 in any case,
for which any underestimate should be similar. For VGLUT1 and
VGLUT2, counts of labeled and unlabeled synaptic terminals on
D1–positive or D1–negative spines and dendrites were made to
ascertain the percent of axospinous and axodendritic terminals
in mouse striatum that possess VGLUT1 or VGLUT2, and to
determine the abundance of each terminal type per unit area of
striatum. The data are presented as group means (±s.e.m.) for
the traits analyzed, unless otherwise stated.
OPEN FIELD
Homozygous Q140 mice have been reported to show hypoki-
nesia in open field by 4 months of age, but heterozygous Q140
males (such as those we studied) have not been found to show
hypoactivity in open field as late as 9 months of age (Menalled
and Howland, personal communication). We thus conducted a
30-min open field test on 12 month-old Q140 and WT mice,
but not on 4-month old mice, using a Noldus EthoVision video
tracking system (Noldus Information Tecknology, Netherlands),
and the SEE software of Drai and Golani (2001). Our goal was
to determine if there are motor deficits in our heterozygous
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Q140 males at 12 months of age, and if so relate them to
the defects in cortical and thalamic input to SPNs. The cir-
cular open field arena has a 200 cm diameter, a non-porous
gray floor, and a 50 cm gray wall, which provides contrast for
video tracking of mice. SEE dichotomizes mouse movements
into lingering episodes and progressionmovements, and provides
endpoints related to locomotion that are robust in identify-
ing differences among mouse strains (Drai et al., 2000; Drai
and Golani, 2001; Kafkafi et al., 2001, 2003; Lipkind et al.,
2004), and between R6/2 HD and WT mice (Reiner et al.,
2012a).
CORTICAL THICKNESS
As part of an effort to determine if cortical pathology was present,
we measured the thickness of primary motor cortex (M1) in our
1-year old mice, since it is among the first affected cortical areas in
human HD that shows thinning (Rosas et al., 2005), and a major
source of input to rodent dorsolateral motor striatum (Reiner
et al., 2003, 2010). Thickness in the present study was measured
in a series of cresyl violet-stained sections from the right hemi-
sphere, from Bregma level 1.94 to Bregma level −0.94. These
sections had been prepared as part of Deng et al. (2013). Blinded
measurements were made of the depth of M1 cortex perpendicu-
lar to the cortical surface at the midpoint of M1 in each section,
using Image J software. Typically seven sections were measured
per animal, and mean thickness determined for each case from
these measurements.
STATISTICAL ANALYSES
Because of the sample size, nonparametric statistics were used
to statistically evaluate differences in terminal size and spatial
abundance, within and between genotypes, for D1+ vs. D1− tar-
gets. For comparisons within genotype for VGLUT+ terminals on
D1+ vs. D1− targets, theWilcoxon signed-rank test was used. For
comparisons between genotypes for VGLUT+ terminals on either
D1+ or D1− targets, theMann-Whitney test was used. In the case
of the VGLUT terminal size frequency distribution data, the dif-
ferences between WT and Q140 mice for a given terminal type
were analyzed using repeated measures ANOVA. Linear regres-
sion was used to assess the relationship between four distinct
open field motor endpoints and the abundance of corticostriatal
or thalamostriatal synaptic terminals on dSPN or iSPN spines in
striatum of 12 month-old Q140 and WT mice. The significance
level was set at p ≤ 0.01 to adjust for multiple comparisons that
were performed in the case of the various EM and behavioral data
sets. The significance level was p ≤ 0.05 in the case of the t-test
used to assess the cortical thickness difference between WT and
Q140 mice.
RESULTS
EM DOUBLE-IMMUNOLABELING STUDIES
VGLUT1 corticostriatal terminals on D1+ or D1− dendrites of
striatal neurons are the least common of the terminal types exam-
ined (about 7% of all corticostriatal terminals), and we thus
collected only a small number of instances of them on either tar-
get in WT or Q140 mice. Though they showed a trend toward
decline in abundance at 12 months in Q140 mice, the results
were variable due to the scarcity of axodendritic corticostriatal
terminals in mice. Thus, we do not present data on VGLUT1
corticostriatal terminals on D1+ vs. D1− striatal dendrites here.
Results for the other corticostriatal or thalamostriatal terminal
types are presented below.
VGLUT1 axospinous terminals
As shown in Table 1, the mean spatial abundance of VGLUT1+
axospinous terminals on D1+ spines was similar to that of
VGLUT1+ axospinous terminals on D1− spines (Table 1), as
also noted in Doig et al. (2010). The mean size of VGLUT1-
positive (VGLUT1+) axospinous terminals on D1+ spines was,
however, less than that of VGLUT1+ axospinous terminals on
D1− spines in WT mice, and the difference trended toward sta-
tistical significance (p = 0.0625). Consistent with this, the size
frequency distributions show that large terminals (> 0.7µm)
were more common on D1− than D1+ spines in WT mice
(Figure 5). The results for Q140 mice were very different than
for WT mice. In particular, the spatial abundance of VGLUT1+
synaptic terminals on D1+ spines was strikingly and significantly
reduced (by 63.3%) in Q140 mice at 12 months, compared to
12-month old WT mice (p = 0.0079). Moreover, unlike in WT
mice, the mean size of VGLUT1+ axospinous terminals on D1+
spines in Q140 mice at 12 months was not less than that of
VGLUT1+ axospinous terminals on D1− spines. In fact, it was
greater, but not significantly so. The size frequency distribution
of the VGLUT1+ axospinous terminals on D1+ spines for WT
and Q140 mice shed further light on these differences. Overall,
the size frequency distribution of VGLUT1+ axospinous termi-
nals on D1+ spines for Q140 mice was significantly different
(p = 0.0001) from that for WT mice (Figure 5). The size fre-
quency distribution graphs also revealed that the D1+ spines
in Q140 mice showed a particular depletion of smaller termi-
nals (i.e., < 0.6µm), thus explaining the trend toward a larger
mean size of VGLUT1+ axospinous terminals on D1+ spines
Table 1 | Abundance and size of VGLUT1-positive axospinous terminals in dorsolateral striatum in 12-month old WT and Q140 mice.
Measured terminal trait WT WT Q140 Q140
D1+ spine D1− spine D1+ spine D1− spine
Terminal abundance (perµm2) 0.082 ± 0.006 0.084 ± 0.006 0.030 ± 0.001* 0.074 ± 0.005
Terminal abundance (as % WT) 100.0% 100.0% 36.7%* 88.0%
Axospinous terminal size (µm) 0.602 ± 0.014 0.676 ± 0.013 0.667 ± 0.034 0.627 ± 0.008
Axospinous terminal size (as % WT) 100.0% 100.0% 110.8% 92.7%
*p = 0.0079–Q140 D1+ axospinous terminal abundance compared to WT D1+ axospinous terminal abundance.
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in Q140 mice than WT mice. In contrast to D1+ spines, the
mean abundance of VGLUT1+ terminals on D1− spines was
not significantly different between Q140 and WT mice (p =
0.2222). Consistent with this, the size frequency distribution of
FIGURE 5 | Graphs showing the size frequency distributions for
VGLUT1+ axospinous synaptic terminals on D1+ (A) and D1− (B)
striatal projection neurons in striatum of 12 month-old WT and
heterozygous Q140 mice. Note that the large shortfall in small terminals
on D1+ spines in Q140 mice.
the VGLUT1+ axospinous terminals on D1− spines in Q140
mice was not significantly different from that for VGLUT1+
axospinous terminals on D1− spines in WT mice (p = 0.1975).
Thus, the loss of axospinous VGLUT1+ corticostriatal termi-
nals in Q140 mice at 12 months is highly preferential for D1+
spines, and seems to especially involve smaller terminals. Note
that our prior study indicates that the decline in spatial abun-
dance of VGLUT1+ axospinous terminals in Q140 mice at 12
months did not stem from a failure to label otherwise surviving
corticostriatal terminals, but rather appears to reflect true termi-
nal loss. VGLUT1-negative axospinous terminals were observed
in the same frequency as VGLUT2+ axospinous terminals in
WT and Q140 mice, meaning there was not a disproportionate
increase in VGLUT1-unlabeled corticostriatal terminals in Q140
mice (Deng et al., 2013).
VGLUT2 axospinous terminals
As shown in Tables 2, 3, the mean spatial abundance of
VGLUT2+ terminals on D1+ spines was similar to that for D1−
spines in WT mice at both 4 and 12 months. The mean size of
VGLUT2+ terminals on D1+ spines in WT mice was also not
significantly different from that of VGLUT2+ terminals on D1−
spines in WT mice, at either 4 or 12 months. The size frequency
distribution data did, however, reveal that VGLUT2+ axospinous
thalamostriatal terminals on D1+ spines in WT mice had a uni-
modal distribution, with a peak at 0.4µm (Figures 6, 7). By
contrast, VGLUT2 axospinous thalamostriatal terminals on D1−
spines in WT mice showed a bimodal distribution (more notably
at 12 months), with peaks at 0.3–0.4µm and 0.5–0.6µm. In the
case of the Q140mutant mice, the mean abundance of VGLUT2+
axospinous synaptic terminals on both D1+ and D1− spines was
reduced by 30–40% compared to WT mice at both 4 and 12
months. The difference was significant for D1+ spines at both
ages (4-months: p = 0.0079; 12-months: p = 0.0079), and at 12
months for D1− spines (p = 0.0079). Mean VGLUT2 axospinous
Table 2 | Abundance and size of VGLUT2-positive axospinous terminals in dorsolateral striatum of 4-month old WT and Q140 mice.
Measured terminal trait WT WT Q140 Q140
D1+ spine D1− spine D1+ spine D1− spine
Terminal abundance (perµm2) 0.051 ± 0.002 0.052 ± 0.003 0.037 ± 0.002* 0.033 ± 0.004
Terminal abundance (as % WT) 100.0% 100.0% 72.1%* 64.1%
Axospinous terminal size (µm) 0.551 ± 0.017 0.526 ± 0.007 0.594 ± 0.022 0.528 ± 0.020
Axospinous terminal size (as % WT) 100.0% 100.0% 107.9% 100.5%
*p = 0.0079–Q140 D1+ axospinous terminal abundance compared to WT D1+ axospinous terminal abundance.
Table 3 | Abundance and size of VGLUT2-positive axospinous terminals in dorsolateral striatum of 12-month old WT and Q140 knock-in mice.
Measured terminal trait WT WT Q140 Q140
D1+ spines D1− spines D1+ spines D1− spines
Terminal abundance (perµm2) 0.044 ± 0.003 0.054 ± 0.003 0.027 ± 0.001* 0.035 ± 0.002**
Terminal abundance (as % WT) 100.0% 100.0% 61.9%* 63.6%**
Axospinous terminal size (µm) 0.560 ± 0.023 0.542 ± 0.014 0.556 ± 0.024 0.533 ± 0.013
Axospinous terminal size (as % WT) 100.0% 100.0% 99.2% 98.3%
*p = 0.0079–Q140 D1+ axospinous terminal abundance compared to WT D1+ axospinous terminal abundance.
**p = 0.0079–Q140 D1− axospinous terminal abundance compared to WT D1− axospinous terminal abundance.
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FIGURE 6 | Graphs showing the size frequency distributions for
VGLUT2+ axospinous synaptic terminals on D1+ (A) and D1−
(B) striatal projection neurons in striatum of 4 month-old WT and
heterozygous Q140 mice. Note that the shortfall in VGUT2+ axospinous
terminals on both D1+ and D1− spines in Q140 mice.
terminal size was, however, no different between Q140 and WT
mice for either VGLUT2 terminals on D1+ spines or those on
D1− spines. Similar overall effects were seen in the size fre-
quency distributions (Figures 6, 7). Significant differences were
seen between Q140 and WT for VGLUT2+ axospinous terminals
on D1+ spines at both 4 months (p = 0.0028) and 12 months
(p = 0.0020), but a significant difference for D1− spines was only
seen at 12 months (p = 0.0019). Thus, the loss of VGLUT2+ ter-
minals from D1+ spines was not progressive between 4 and 12
months, but that for D1− spines appeared to be perhaps progres-
sive. For both VGLUT2+ terminals on D1+ and on D1− spines
in Q140 mice, the loss occurred at both the higher and lower ends
of the size ranges, explaining why the mean size of VGLUT2+
axospinous terminals in Q140 mice was unaltered compared to
WT mice. Note again that our prior study (Deng et al., 2013)
indicated that the shortfall in the spatial abundance of VGLUT2+
axospinous terminals in Q140 mice did not stem from a fail-
ure to label otherwise surviving thalamostriatal terminals, but
rather appears to reflect true terminal shortfall. VGLUT2-negative
axospinous terminals were observed in the same frequency as
VGLUT1+ axospinous terminals inWT and Q140 mice, meaning
there was not a disproportionate increase in VGLUT2-unlabeled
thalamostriatal terminals in Q140 mice.
VGLUT2 axodendritic terminals
As shown in Tables 4, 5, the mean spatial abundance
of VGLUT2+ synaptic terminals on D1+ dendrites was
FIGURE 7 | Graphs showing the size frequency distributions for
VGLUT2+ axospinous synaptic terminals on D1+ (A) and D1−
(B) striatal projection neurons in striatum of 12 month-old WT and
heterozygous Q140 mice. Note that the shortfall in VGUT2+ axospinous
terminals on both D1+ and D1− spines in Q140 mice.
indistinguishable from that on D1− dendrites for WT mice,
at both 4 and 12 months of age. The mean size of VGLUT2+
synaptic terminals on D1+ dendrites was also indistinguishable
from that on D1− dendrites for WT mice, at both ages. Overall,
VGLUT2+ axodendritic endings in WT mouse striatum were
far less common than VGLUT2+ axospinous endings, with
the axospinous to axodendritic ratio for VGLUT2 synaptic
terminals being about 4–1. The Q140 mice showed no consistent
or significant differences in the mean spatial abundance of
VGLUT2 axodendritic terminals on D1+ vs. D1− dendrites
at either 4 or 12 months. They also showed no significant
differences from WT in mean spatial abundance for either
axodendritic terminal type at either age. The mean size of
VGLUT2+ synaptic terminals on D1+ dendrites in Q140 mice
was also indistinguishable from that on D1− dendrites for both
age groups, and the mean size of VGLUT2+ synaptic terminals
on dendrites of either type was also indistinguishable at either
age from that in WT mice. The size frequency distributions
(Figures 8, 9), however, suggested a possible loss of larger
VGLUT2 axodendritic thalamostriatal terminals on D1− spines
in Q140 mice at both ages. Statistical analysis, however, did
not detect significant differences between WT and Q140 in the
size frequency distributions for VGLUT2+ terminals on D1+
or D1− dendrites at either age. Our overall results suggest loss
of axodendritic VGLUT2+ terminals in Q140 mice was not
prominent, but more detailed study will be needed to determine
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Table 4 | Abundance and size of VGLUT2-positive axodendritic terminals in dorsolateral striatum of 4-month old WT and Q140 knock-in mice.
Measured terminal trait WT WT Q140 Q140
D1+ dendrite D1− dendrite D1+ dendrite D1− dendrite
Terminal abundance (perµm2) 0.013 ± 0.002 0.011 ± 0.003 0.009 ± 0.003 0.011 ± 0.002
Terminal abundance (as % WT) 100.0% 100.0% 65.9% 101.0%
Axodendritic terminal size (µm) 0.583 ± 0.060 0.607 ± 0.046 0.581 ± 0.035 0.569 ± 0.048
Axodendritic terminal size (as % WT) 100.0% 100.0% 99.7% 93.6%
Table 5 | Abundance and size of VGLUT2-positive axodendritic terminals in dorsolateral striatum of 12-month old WT and Q140 knock-in mice.
Measured terminal trait WT WT Q140 Q140
D1+ dendrites D1− dendrites D1+ dendrites D1− dendrites
Terminal abundance (perµm2) 0.010 ± 0.002 0.013 ± 0.002 0.009 ± 0.001 0.006 ± 0.002
Terminal abundance (as % WT) 100.0% 100.0% 88.1% 41.6%
Axodendritic terminal size (µm) 0.610 ± 0.028 0.622 ± 0.026 0.601 ± 0.040 0.646 ± 0.078
Axodendritic Terminal size (as % WT) 100.0% 100.0% 98.6% 103.8%
FIGURE 8 | Graphs showing the size frequency distributions for
VGLUT2+ axodendritic synaptic terminals on D1+ (A) and D1−
(B) striatal projection neurons in striatum of 4 month-old WT and
heterozygous Q140 mice. Note that VGUT2+ axodendritic terminals on
both D1+ and D1− spines are largely similar in abundance in WT and Q140
mice, but with some possible shortfall in large terminals on D1− dendrites.
if there is slight loss of larger VGLUT2+ synaptic terminals from
D1− dendrites.
CORRELATION BETWEEN OPEN FIELD MOTOR ENDPOINTS AND VGLUT
TERMINAL LOSS
Q140 mice showed a mild hypokinesia at 12 months, which was
reflected in several open field motor parameters. For example,
FIGURE 9 | Graphs showing the size frequency distributions for
VGLUT2+ axodendritic synaptic terminals on D1+ (A) and D1−
(B) striatal projection neurons in striatum of 12 month-old WT and
heterozygous Q140 mice. Note that VGUT2+ axodendritic terminals on
both D1+ and D1− spines are largely similar in abundance in WT and Q140
mice, but with some possible shortfall in large terminals on D1− dendrites.
Q140 mice showed a decrease in overall movement, progres-
sion segment length (p = 0.003), and maximum speed, and
an increase in the number of pauses (p = 0.002) (Table 6). Of
note, distance traveled, progression segment length and max-
imum speed were directly correlated with the abundance of
VGLUT1+ corticostriatal terminals on D1+ spines across the
WT and Q140 mice (i.e., n = 10), while number of pauses was
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Table 6 | Correlation between open field behavior and VGLUT terminal loss in 1-year old Q140 and WT mice.
Distance traveled Progression segment Maximum speed Number of stops
in centimeters length in centimeters in cm/sec per unit distance
Q140 as % WT 84.2% (p = 0.085) 76.4% (p = 0.003) 89.3% (p = 0.074) 130.3% (p = 0.002)
Correlation with VG1+ terminals on D1+ spines 0.653 (p = 0.0366) 0.900 (p = 0.0003) 0.680 (p = 0.0292) −0.846 (p = 0.0014)
Correlation with VG1+ terminals on D1− spines 0.335 (p = 0.344) 0.485 (p = 0.155) 0.441 (p = 0.202) −0.570 (p = 0.060)
Correlation with VG2+ terminals on D1+ spines 0.304 (p = 0.394) 0.629 (p = 0.052) 0.271 (p = 0.448) −0.716 (p = 0.0229)
Correlation with VG2+ terminals on D1− spines 0.187 (p = 0.606) 0.579 (p = 0.080) 0.251 (p = 0.485) −0.598 (p = 0.086)
With p < 0.01 required for significance (Bold).
inversely correlated. The correlations for progression segment
length and stops were highly significant. By contrast, none of
these motor parameters was significantly correlated with the
abundance of VGLUT1+ axospinous terminals on D1− spines.
Similarly, VGLUT2+ axospinous thalamostriatal terminal abun-
dance on neither D1+ nor D1− spines was significantly cor-
related with any of these motor endpoints. Thus, the loss of
VGLUT1+ axospinous terminals on D1+ spines at 12 months is
significantly and selectively linked to the mild hypokinesia seen in
the Q140 mice.
CORTICAL THICKNESS
The thickness of M1 in Q140 mice at 12 months was
1.30 ± 0.03mm, compared to 1.33 ± 0.03mm in WT mice
at 12 months. This difference was not significant by a t-test
(p = 0.405).
DISCUSSION
In the present study, we found that dSPNs show a substantial and
selective loss of about 65% of axospinous cortical input in Q140
mice by 12 months of age (Deng et al., 2013). Axospinous corti-
cal input to iSPNs was, however, largely unchanged. In our prior
study, we also reported that striatal volume in 12-month old Q140
mice was unchanged. In the present study, we also found no evi-
dence of cortical thinning in Q140 mice at 12 months of age.
Additionally, Rising et al. (2011) did not observe cortical neuron
loss in Q140 mice at this age. Thus, the preferential loss of cortical
terminals on D1+ spines is unlikely to be due to either cortical or
striatal neuron loss per se, but rather selective loss of axospinous
terminals from dSPN spines during disease progression. By con-
trast to the corticostriatal projection, loss of axospinous thalamic
input to dSPNs and iSPNs in Q140 mice was comparable, and
already evident at 4 months of age. The loss of cortical input to
D1+ spines at 12 months of age was highly correlated with a
slight but significant decrease in locomotor activity in open field,
but loss of thalamic input was not. The implications of our find-
ings for the pathophysiology and pathogenesis of human HD are
discussed in more detail below.
CORTICAL INPUT LOSS TO STRIATAL PROJECTION NEURONS IN HD
Numerous imaging studies have reported cortical thinning in pre-
manifest HD, coupled with cortical white matter loss (DiProspero
et al., 2004; Kipps et al., 2005; Reading et al., 2005; Rosas et al.,
2005, 2006; Ciarmiello et al., 2006; Paulsen et al., 2006; Hobbs
et al., 2010a; Aylward et al., 2011; Dumas et al., 2012), and stri-
atal hypoactivation (Grafton et al., 1992; Paulsen et al., 2004;
Ciarmiello et al., 2006; Wolf et al., 2012). Although premanifest
cortical and striatal neuron loss have not been quantified, they are
generally thought to be minimal (Vonsattel et al., 1985; Augood
et al., 1997; Vonsattel and DiFiglia, 1998; Glass et al., 2000; Deng
et al., 2004; Nopoulos et al., 2010). In this context then, our
results in Q140 mice are of interest, as they suggest that corti-
costriatal synaptic pruning may occur during premanifest HD
preferentially on direct pathway neurons. Such premanifest corti-
costriatal terminal loss might be expected as an early reflection of
a pathogenic process that in symptomatic HD causes significant
regional thinning of cerebral cortex and loss of cortical pyramidal
neurons (Rosas et al., 2003; Kassubek et al., 2004b; Douaud et al.,
2006; Mühlau et al., 2007).
Although loss of corticostriatal input prior to significant stri-
atal neuron loss has not been directly demonstrated neuropatho-
logically in either human HD or in prior studies of mouse HD
models, other types of data from mouse models are consistent
with our findings in Q140 mice. For example, loss of presynap-
tic markers such as Lin7b and synaptophysin from cortex, loss
of postsynaptic markers such as PSD-95 from striatum, loss of
dendritic spines from SPNs, and/or loss of excitatory synaptic
terminals in striatum are observed in early symptomatic R6/2
and YAC128 mice (Klapstein et al., 2001; Cepeda et al., 2003;
Graham et al., 2009; Cummings et al., 2010; Singaraja et al., 2011).
Data from R6/2 and YAC128 HD mice suggest that dSPNs in
particular show reduced glutamatergic corticostriatal excitation
at ages at which there is no loss of dSPNs (Benn et al., 2007;
André et al., 2011a,b; Reiner et al., 2012a,b). The small size of
the corticostriatal terminals preferentially lost in Q140 mice from
dSPNs by 12 months of age in our study suggests that they may
predominantly represent input from intratelencephalically pro-
jecting (IT)—type corticostriatal neurons (Wilson, 1987; Wright
et al., 1999, 2001; Reiner et al., 2003, 2010), which our work
and that of others suggests represent the main but not exclusive
source of cortical input to the spines of dSPNs (Lei et al., 2004;
Cepeda et al., 2008; Reiner et al., 2010; Spigolon et al., 2013;
Wall et al., 2013). Such loss of drive to the “go” neurons of the
direct pathway would be expected to cause behavioral hypoac-
tivity (Albin et al., 1989; Kravitz et al., 2010; Spigolon et al.,
2013), which is observed as a major symptom as both heterozy-
gous and homozygous Q140 mice age (Menalled et al., 2003;
Hickey et al., 2008; Rising et al., 2011). Loss of cortical drive
to dSPNs may thus explain the significant correlation we found
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specifically between the abundance of axospinous cortical termi-
nals andmotor activity in open field across 12-month oldWT and
heterozygous Q140 mice. If a similar event occurs in humans, it
could help explain the growingmotor slowing evident in preman-
ifest HD (Siemers et al., 1996; de Boo et al., 1997; Kirkwood et al.,
1999, 2000; Blekher et al., 2004; Rao et al., 2008; Biglan et al.,
2009; Bechtel et al., 2010; Delval et al., 2011; Rao et al., 2011;
Tabrizi et al., 2011; Turner et al., 2011). It is possible, however,
that the link we observed between loss of axospinous terminals
from dSPN spines and motor slowing in 12-month Q140 mice
reflects the common action of a general disease-related decline.
Nonetheless, we saw no correlation between thalamic terminal
loss to either dSPN or iSPN spines on one hand and motor slow-
ing on the other. Such a correlation might be expected if terminal
loss from SPNs and motor slowing represent the common dele-
terious action of a generalized disease-related decline on brain
pathology and motor abnormalities.
In both R6/2 and YAC128 HD mice, the loss in corticostri-
atal drive to the striatum is preceded by earlier corticostriatal
hyperactivity (Cepeda et al., 2003; Rebec et al., 2006; Joshi et al.,
2009; André et al., 2011a). Corticostriatal terminal dysfunction,
changes in membrane properties of SPNs, and altered potassium
uptake by astroglia all appear to contribute to the SPN hyperac-
tivity (Cepeda et al., 2003; André et al., 2011a; Tong et al., 2014).
The direct pathway neurons in particular show early enhanced
and later reduced corticostriatal excitation (André et al., 2011a,b).
The reduced corticostriatal excitation reflects the loss of corticos-
triatal input rather than reduced striatal excitability, since dSPNs
remain more depolarized at rest, and have elevated input resis-
tances (Cepeda et al., 2003; Singaraja et al., 2011; Estrada-Sanchez
and Rebec, 2013). The preferential loss of cortical input to dSPNs
is of interest in light of the possibility that the loss is neuroprotec-
tive. The dSPNs projecting to the internal pallidal segment (GPi)
are the most resistant projection neuron type in HD (Deng et al.,
2004), and a downregulation in excitatory cortical input to them
could help explain not only why striato-GPi dSPNs resist death
better in human HD than do other striatal SPNs, but also may
explain the emergence of resistance to corticostriatal excitotoxi-
city as HD mice age (Hansson et al., 1999, 2001; Graham et al.,
2009). The corticostriatal synaptic pruning may, thus, involve
activity-dependent mechanisms, rather than an HD-driven corti-
cal pathology selective for the cortical input to dSPNs (Tian et al.,
2010; Schafer et al., 2012). To this end, it would also be useful to
know if HD differentially affects the two types of corticostriatal
neurons, the IT-type and the pyramidal tract-type (or PT-type)
(Reiner et al., 2010), and their synapse formation with their stri-
atal target neurons. For example, it could be the case that the HD
mutation more greatly affects the behavior of IT-type neurons,
rendering them more active than PT-type neurons, which ulti-
mately then leads to the preferential loss of IT-type terminals from
dSPN spines.
Our finding of loss of axospinous cortical input to dSPNs but
not to iSPNs at 12 months of age in Q140 heterozygous mice is
relevant to the possible role of brain-derived neurotrophic factor
(BDNF) insufficiency in HD pathogenesis. A number of studies
have shown that striatal neurons depend on BDNF for survival
(Mizuno et al., 1994; Widmer and Hefti, 1994; Nakao et al.,
1995; Martınez-Serrano and Bjorklund, 1996; Alcantara et al.,
1997; Ivkovic and Ehrlich, 1999; Aggerman and Ernfors, 2003;
Grosse et al., 2005; Ventimiglia et al., 1995), and production and
delivery of BDNF from cortex to striatum is diminished in HD
and animal models of HD (Cattaneo et al., 2001, 2005; Zuccato
et al., 2001, 2003, 2005, 2008; Gauthier et al., 2004; Zuccato and
Cattaneo, 2007; Reiner et al., 2012b). Moreover, studies in vari-
ous mutant mice indicate that diminished cortical production of
BDNF harms striatal neurons (Gorski et al., 2003; Baquet et al.,
2004; Canals et al., 2004; Saylor et al., 2006; Strand et al., 2007),
and intrastriatal BDNF delivery or selective forebrain overexpres-
sion of BDNF improves symptoms in transgenic HDmice (Canals
et al., 2004; Gharami et al., 2008; Xie et al., 2010; Giralt et al.,
2011). Under these circumstances, preferential loss of axospinous
cortical terminals from dSPNs might be expected to cause their
greater vulnerability in HD and HD models than iSPNs. As has
been shown, nonetheless, iSPNs are more vulnerable in both
human HD and genetic models of HD (Reiner et al., 1988; Glass
et al., 2000; Menalled et al., 2000; Sun et al., 2002; Canals et al.,
2004; Deng et al., 2004). A number of lines of evidence, how-
ever, show that iSPNs are much more vulnerable than dSPNs
to BDNF deprivation (Canals et al., 2004; Baydyuk et al., 2011;
Reiner et al., 2012b). Moreover, BDNF production by the type of
neuron whose axospinous input to dSPNs is lost (i.e., the IT-type)
appears to be less than for the other major type of corticostriatal
neuron, the PT-type (Doyle et al., 2008), which is the preferential
source of axospinous input to iSPNs (Reiner et al., 2010). Thus,
if IT-type terminals are preferentially lost from dSPNs early in
premanifest human HD gene carriers, the lesser dependence of
dSPNs on BDNF and the lesser BDNF production by IT-type neu-
rons may explain why this does not cause the dSPNs to be the
more vulnerable neuron type in HD.
Although the loss of cortical input to dSPNs may help explain
the hypokinesia seen very early in the course of HD before stri-
atal neuron loss, as in our 12-month old Q140 heterozygous
mice, hyperactivity in a rearing test has been reported in homozy-
gous Q140 mice at 1 month of age (Menalled et al., 2003).
Hyperactivity in a rearing test has not, however, been observed at
2.5 months of age in Q140 heterozygous mice, in whom the phe-
notype is slowed compared to Q140 homozygous mice (Rising
et al., 2011). Thus, it is uncertain that Q140 heterozygous mice
show an early hyperactivity similar to that reported in Q140
homozygous mice. In any event, the basis of the rearing hyperac-
tivity in homozygous Q140 mice at 2 months of age is uncertain,
and not likely to be attributable to cortical input loss since the
loss we observed here in heterozygous Q140 mice does not occur
until much later. In our prior EM single-label study of Q140
heterozygous mice (Deng et al., 2013), we found a deficiency in
thalamic input to striatal dendrites already at 1 month of age,
which persists beyond this age. As thalamic input ends on the
dendritic shafts of both cholinergic interneurons and striatal pro-
jection neurons (Lapper and Bolam, 1992; Sidibé and Smith,
1999; Salin and Kachidian, 1998; Giorgi et al., 2001; Bacci et al.,
2002, 2004; Smith et al., 2004), from our EM single-label stud-
ies alone it was uncertain if the missing thalamic axodendritic
input occurs for cholinergic interneurons or striatal projection
neurons. In an EM double-label study to examine this, we found
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that cholinergic striatal interneurons in heterozygous Q140 mice,
in particular, show a 40% deficiency in axodendritic thalamic
input at 1 month of age (Deng et al., 2012). If a similar phe-
nomenon occurs in homozygous Q140mice (which seems likely),
it may explain their reported hyperkinesia at 1 month, as the loss
of thalamic input to cholinergic neurons would be predicted to
more greatly lessen the responses of iSPNs than dSPNs to cortical
drive (Smith et al., 2011), which models of basal ganglia function
predict should cause hyperkinesia (Albin et al., 1989). The early
rearing hyperkinesia at 2 months in homozygous Q94 knock-in
mice (Menalled et al., 2002) and the open field hyperactivity at 3
months in heterozygous YAC128 mice (Slow et al., 2003), both
before striatal projection neuron loss, might be explainable by
this mechanism as well. An early deficiency in large axodendritic
thalamic terminals on iSPNs, suggested by the present findings,
may also contribute to the early hyperkinesia. Subsequent loss
of cortical input to dSPNs during premanifest stages may lead to
hypokinesia becoming the major motor manifestation.
THALAMIC INPUT LOSS TO STRIATAL PROJECTION NEURONS IN HD
Thalamostriatal projections end on the spines and dendrites
of SPNs, with the proportion of spine vs. dendrite targeting
being about 2:1 in rats and 4:1 in mice (Doig et al., 2010;
Deng et al., 2013; Lei et al., 2013; Huerta-Ocampo et al., 2014).
Thalamostriatal terminals are about half as abundant as corticos-
triatal terminals on the spines of SPNs, though more common on
dendrites (Deng et al., 2013; Huerta-Ocampo et al., 2014). In gen-
eral, dSPNs have been reported to receive a greater thalamic input
than iSPNs in rats andmonkeys (Sidibé and Smith, 1996; Lei et al.,
2013). In the present study, we found a very similar abundance of
VGLUT2+ terminals on D1+ vs. D1− spines and dendrites in 4
month− and 12 month-old WT mice, as have others (Doig et al.,
2010; Huerta-Ocampo et al., 2014). Similarly, Wall et al. (2013)
reported that dSPNs and iSPNs in mice receive input from rela-
tively equal numbers of thalamic neurons. Nonetheless, the D1+
and D1− synaptic targets differ for WT mice in the shape of their
size frequency distribution curves, with dSPN spines in 12-month
old WT mice receiving synaptic contact from thalamic terminals
with a size peak at 0.4µm, and iSPN spines in 12-month old
WT mice receiving synaptic input from populations of terminals
with size peaks at 0.3–0.4µm and 0.5–0.6µm. This suggests that
there may be thalamostriatal neuron subtypes that differ in their
relative targeting of the two SPN types.
In any event, the present study shows that the deficiency in
thalamic input to SPN spines that we previously demonstrated
occurs early in the lifespan of Q140 mice (Deng et al., 2013)
is largely comparable for dSPNs and iSPNs spines, and is not
notably progressive from 4 to 12 months (except perhaps some-
what for D1− spines). Abnormalities in the part of thalamus
projecting to striatum, such as increased GFAP expression, loss of
the adhesion molecule tenascin-C, and loss of the synaptic pro-
tein complexin II, have been observed in other mouse models of
HD (Kusakabe et al., 2001; Freeman and Morton, 2004). Given
the thalamic atrophy and hypometabolism reported in preman-
ifest HD, which eventually progresses to intralaminar thalamic
neuron loss (Heinsen et al., 1999), an early deficiency in thalamic
input to striatum may also occur in human HD victims (Paulsen
et al., 2004; Feigin et al., 2007; Aylward et al., 2011). How this
slight defect might affect behavior is uncertain. The absence of
hypoactivity prior to 9 months in male Q140 heterozygous mice
(Menalled and Howland, personal communication) suggests that
the deficiency in thalamic input already seen at 1–4 months is not
sufficient to causemotor hypoactivity. Similarly, hyperactivity has
not been observed in male Q140 heterozygous mice (Rising et al.,
2011) at 2.5 months of age or beyond, which suggests that the
deficiency in thalamic but not cortical input already seen at 1–4
months could not by itself cause this motor abnormality either.
Since thalamic input to striatum is thought to play a role in atten-
tional mechanisms concerning motor planning and preparedness
(Smith et al., 2004), more subtle behavioral tests may be required
to detect the effect of the early deficiency in thalamic input to
SPNs in Q140 heterozygous mice.
Of relevance to the basis of the thalamostriatal shortfall
in Q140 mice, our observation that the deficiency in thala-
mic input does not notably progress from 4 to 12 months,
except perhaps for iSPNs, and our prior finding that thalam-
ostriatal input is already deficient at 1 month in Q140 mice
raises the possibility that the deficiency involves an early devel-
opmental defect rather than a later pathological event. Consistent
with this, striatal expression of proteins critical to thalamos-
triatal synapse formation, such as the semaphorin 3E receptor
Plexin-D1 signaling complex, are significantly reduced early in
the lifespan of several transgenic or knock-in HD mice (Kuhn
et al., 2007; Ding et al., 2011), and in human HD as well
(Strand et al., 2007).
REGIONAL PATTERN OF CORTICAL AND THALAMIC TERMINAL LOSS
We limited our analyses to dorsolateral motor striatum, and saw
selective loss of presumptive IT-type corticostriatal axospinous
terminals from dSPNs at 12 months, and relatively equal loss
of thalamostriatal axospinous terminals from dSPNs and iSPNs
already at 4 months. The striatum is, however, a heterogeneous
structure that consists of distinct striosomal and matrix compart-
ments. By analyzing dorsolateral striatum, we focused on matrix
compartment SPNs and their motor function. As the organiza-
tion of cortical and thalamic input to striosomes differs from that
to matrix (Reiner et al., 2010; Crittenden and Graybiel, 2011),
and as HDmay differentially affect these two structures (Ferrante
et al., 1987; Seto-Ohshima et al., 1988; Hedreen and Folstein,
1995; Deng et al., 2004; Crittenden and Graybiel, 2011; Waldvogel
et al., 2012), we cannot know if the pattern of cortical and thala-
mic terminal loss we saw for dorsolateral matrix is also the case
for striosomes. Moreover, the matrix compartment is regionally
heterogeneous in terms of the parts of cortex and thalamus from
which it receives input (Reiner et al., 2003, 2010; Crittenden and
Graybiel, 2011). Thus, we cannot know if the pattern of cortical
and thalamic terminal loss we saw for dorsolateral matrix com-
partment is the case for all of matrix. These issues will be of
interest to address in future studies.
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